Host: The Japanese Society of Toxicology
In the conventional corneal transplantation, the shortage of donated eyes and rejection have been the main problems.
To solve these problems, we have been developing corneal regenerative therapy using human iPS cells. Using human iPS cells, we have succeeded in developing the ocular organoid system (self-formed ectodermal autonomous multi-zone: named SEAM) that recapitulates the development of the entire eye (Nature 2016). We developed a technology for producing iPS cell-derived corneal epithelial cell sheets using this SEAM method and started first-in-human clinical research in 2019.
